Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).

IF 1.4 4区 医学 Q3 RHEUMATOLOGY
ARP Rheumatology Pub Date : 2023-04-01
Filipe Oliveira Pinheiro, Maria Seabra Rato, Pedro Madureira, Filipe Araújo, Maria João Salvador, Vanessa Fraga, Luisa Brites, Filipe Cunha Santos, Augusto Silva, Ana Rita Lopes, Margarida Cruz, João Paulo Vilas Boas, Maria Pontes Ferreira, Beatriz Samões, Tiago Beirão, Inês Santos, Daniel Carvalho, Lúcia Costa, Miguel Bernardes
{"title":"Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).","authors":"Filipe Oliveira Pinheiro,&nbsp;Maria Seabra Rato,&nbsp;Pedro Madureira,&nbsp;Filipe Araújo,&nbsp;Maria João Salvador,&nbsp;Vanessa Fraga,&nbsp;Luisa Brites,&nbsp;Filipe Cunha Santos,&nbsp;Augusto Silva,&nbsp;Ana Rita Lopes,&nbsp;Margarida Cruz,&nbsp;João Paulo Vilas Boas,&nbsp;Maria Pontes Ferreira,&nbsp;Beatriz Samões,&nbsp;Tiago Beirão,&nbsp;Inês Santos,&nbsp;Daniel Carvalho,&nbsp;Lúcia Costa,&nbsp;Miguel Bernardes","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Despite years of experience with biological disease modifying anti-rheumatic drugs (bDMARD) in rheumatoid arthritis (RA), little is known about differences in infectious risk among bDMARDs. The aim of this study was to assess the incidence and type of infections in RA patients on bDMARDs and to determine possible predictors.</p><p><strong>Methods: </strong>A retrospective multicenter cohort study that included patients registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt) with RA, and exposed to at least one bDMARD until April 2021. RA patients under bDMARD and with at least one episode of severe infection (SI), defined as infection that requires hospitalization, use of parenteral antibiotics or that resulted in death, were compared to patients with no report of SI. Demographic and clinical data at baseline and at the time of each SI were collected to establish comparisons between different groups of bDMARDs. Comparisons between different bDMARDs were assessed and logistic regression was performed to identify predictors of SI.</p><p><strong>Results: </strong>We included 3394 patients, 2833 (83.5%) female, with a mean age at RA diagnosis of 45.5±13.7 years. SI was diagnosed in 142 of the 3394 patients evaluated (4.2%), totaling 151 episodes of SI. At baseline, patients with SI had a significantly higher proportion of prior orthopedic surgery, asthma, interstitial lung disease, chronic kidney disease and corticosteroid use, higher mean age and longer median disease duration at first bDMARD. Nine patients died (6.0%). Ninety-two SI (60.9%) occurred with the first bDMARD, the majority leading to discontinuation of the bDMARD within 6 months (n=75, 49.7%), while 65 (43.0%) restarted the same bDMARD and 11 (7.3%) switched to another bDMARD (6 of them to a different mechanism of action). In the multivariate analysis, we found that chronic kidney disease, asthma, infliximab, corticosteroid use, interstitial lung disease, previous orthopedic surgery, higher Health Assessment Questionnaire and DAS284V-ESR are independent predictors of SI.</p><p><strong>Conclusion: </strong>This study described the incidence and types of SI among Portuguese RA patients on biologics, identifying several predictors of SI, both globally and with different bDMARDs. Physicians should be aware of the real-word infectious risk in RA patients on bDMARDs when making treatment decisions.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 2","pages":"111-119"},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ARP Rheumatology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Despite years of experience with biological disease modifying anti-rheumatic drugs (bDMARD) in rheumatoid arthritis (RA), little is known about differences in infectious risk among bDMARDs. The aim of this study was to assess the incidence and type of infections in RA patients on bDMARDs and to determine possible predictors.

Methods: A retrospective multicenter cohort study that included patients registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt) with RA, and exposed to at least one bDMARD until April 2021. RA patients under bDMARD and with at least one episode of severe infection (SI), defined as infection that requires hospitalization, use of parenteral antibiotics or that resulted in death, were compared to patients with no report of SI. Demographic and clinical data at baseline and at the time of each SI were collected to establish comparisons between different groups of bDMARDs. Comparisons between different bDMARDs were assessed and logistic regression was performed to identify predictors of SI.

Results: We included 3394 patients, 2833 (83.5%) female, with a mean age at RA diagnosis of 45.5±13.7 years. SI was diagnosed in 142 of the 3394 patients evaluated (4.2%), totaling 151 episodes of SI. At baseline, patients with SI had a significantly higher proportion of prior orthopedic surgery, asthma, interstitial lung disease, chronic kidney disease and corticosteroid use, higher mean age and longer median disease duration at first bDMARD. Nine patients died (6.0%). Ninety-two SI (60.9%) occurred with the first bDMARD, the majority leading to discontinuation of the bDMARD within 6 months (n=75, 49.7%), while 65 (43.0%) restarted the same bDMARD and 11 (7.3%) switched to another bDMARD (6 of them to a different mechanism of action). In the multivariate analysis, we found that chronic kidney disease, asthma, infliximab, corticosteroid use, interstitial lung disease, previous orthopedic surgery, higher Health Assessment Questionnaire and DAS284V-ESR are independent predictors of SI.

Conclusion: This study described the incidence and types of SI among Portuguese RA patients on biologics, identifying several predictors of SI, both globally and with different bDMARDs. Physicians should be aware of the real-word infectious risk in RA patients on bDMARDs when making treatment decisions.

葡萄牙类风湿性关节炎患者在生物治疗下的严重感染——一项多中心、全国性研究(sipra - b研究)
尽管生物疾病修饰抗风湿药物(bDMARD)治疗类风湿性关节炎(RA)已有多年的经验,但对bDMARD之间感染风险的差异知之甚少。本研究的目的是评估bdmard类风湿性关节炎患者感染的发生率和类型,并确定可能的预测因素。方法:一项回顾性多中心队列研究,纳入在葡萄牙风湿病登记处(Reuma.pt)登记的RA患者,并在2021年4月之前暴露于至少一种bDMARD。接受bDMARD治疗且至少有一次严重感染(SI)发作的RA患者与未报告SI的患者进行比较,严重感染定义为需要住院治疗、使用肠外抗生素或导致死亡的感染。收集基线和每次SI时的人口学和临床数据,以建立不同bdmard组之间的比较。评估不同bdmard之间的比较,并进行逻辑回归以确定SI的预测因子。结果:我们纳入3394例患者,其中2833例(83.5%)为女性,RA诊断时的平均年龄为45.5±13.7岁。3394例患者中有142例(4.2%)被诊断为SI,共151次SI发作。在基线时,SI患者既往骨科手术、哮喘、间质性肺疾病、慢性肾脏疾病和皮质类固醇使用的比例明显较高,首次bDMARD时的平均年龄较高,中位疾病持续时间较长。死亡9例(6.0%)。92例SI(60.9%)发生在第一次bDMARD中,大多数导致在6个月内停止bDMARD (n=75, 49.7%), 65例(43.0%)重新开始使用相同的bDMARD, 11例(7.3%)切换到另一个bDMARD(其中6例使用不同的作用机制)。在多因素分析中,我们发现慢性肾脏疾病、哮喘、英夫利昔单抗、皮质类固醇使用、间质性肺疾病、既往骨科手术、较高的健康评估问卷和DAS284V-ESR是SI的独立预测因素。结论:本研究描述了葡萄牙使用生物制剂的RA患者SI的发生率和类型,确定了全球和不同bdmard患者SI的几个预测因素。在做出治疗决定时,医生应该意识到服用bdmard的RA患者的真实感染风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信